Key Takeaways BMY's growth drugs like Opdivo, Reblozyl and Breyanzi are offsetting steep declines from legacy brands.AMGN's revenue base is supported by Repatha, Tezspire and rare disease drugs added via Horizon acquisition.BMY trades at a lower forward P/E, while AMGN shows stronger sales and EPS growth outlook.Bristol Myers Squibb (BMY) and Amgen (AMGN) are among the largest global biotechnology companies with broad and diverse portfolios.Bristol Myers Squibb is focused on discovering, developing and deli ...